Overcoming Multi-Drug-Resistant Klebsiella pneumoniae Infections

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Antimicrobial resistance (AMR) poses a significant global health challenge, affecting both Gram-positive and Gram-negative bacteria.
• Klebsiella pneumoniae (K. pneumoniae), a Gram-negative bacterium, is a major cause of nosocomial infections and has developed resistance, leading to multi-drug resistant (MDR), extensively drug-resistant, and pan-drug-resistant strains.
• Conventional antibiotics are increasingly ineffective against MDR K. pneumoniae, necessitating the exploration of alternative therapeutic strategies.

Purpose of the Study:

• To review the latest alternative treatment methods effective against multi-drug resistant Klebsiella pneumoniae infections.
• To identify and summarize emerging therapeutic options beyond traditional antibiotics for combating MDR K. pneumoniae.

Main Methods:

• A comprehensive literature search was conducted using PubMed, MEDLINE, and Google Scholar.
• Keywords included "multi-drug-resistant K. pneumoniae," "AMR," and "alternative treatments."
• A total of 183 articles were selected based on predefined inclusion and exclusion criteria.

Main Results:

• Several novel therapeutic options show promise against MDR K. pneumoniae.
• These include odilorhabdins, advanced drug delivery systems, antibody drug conjugation, nano-antibiotics, bacteriocins, probiotics, fecal microbiota transplantation, predatory bacteria, combination antibiotic therapies, double-carbapenem regimens, synthetic lipopeptides, and phage therapy.

Conclusions:

• Emerging alternative treatments offer new avenues for managing difficult-to-treat MDR K. pneumoniae infections.
• These innovative approaches are crucial for addressing the growing threat of antimicrobial resistance and improving patient outcomes.